We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
Read MoreHide Full Article
Key Takeaways
NVS to acquire SNV4818 program for $2B upfront, targeting PI3K mutations in breast cancer.
SNV4818 aims for better tolerability, enabling combos and broader use in HR /HER2- patients.
NVS strengthens pipeline amid Entresto generics, leveraging Kisqali and new oncology assets.
Novartis (NVS - Free Report) is doubling down on precision oncology with a targeted bolt-on acquisition that strengthens its position in one of the largest segments of breast cancer.
Novartis has agreed to acquire a pan-mutant–selective PI3Kα inhibitor program from Synnovation Therapeutics, anchored by lead asset SNV4818.
The transaction aligns squarely with Novartis’ oncology strategy in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer — a large and well-characterized market where innovation has increasingly shifted toward targeted and combination therapies.
Financial Terms of NVS’ Deal With Synnovation
The deal includes a $2 billion upfront payment and up to $1 billion in milestones, signaling high conviction in the program despite its early-stage status.
The transaction is slated to be closed in the first half of 2026.
Strategic Rationale Behind NVS’ Acquisition
SNV4818 is designed to target the mutated PI3Kα enzyme found in cancer cells while sparing the wild-type (normal) PI3Kα in healthy cells.
Approximately 40% of HR+/HER2- breast cancer patients harbor PIK3CA mutations, a subgroup associated with poorer prognosis. This creates a sizable, biomarker-defined patient population where targeted therapies can command premium pricing and strong adoption, provided they demonstrate clear differentiation.
Earlier-generation PI3K inhibitors have struggled with tolerability due to off-target effects on normal cells, often limiting dosing intensity and duration.
By contrast, SNV4818’s mutant-selective approach aims to improve tolerability and safety, enable more consistent dosing, expand usage in earlier lines of therapy, and enhance combination potential with endocrine therapy and CDK inhibitors.
SNV4818 is currently in phase I/II development.
For Novartis, this opportunity is not just about monotherapy potential. The real upside lies in combination regimens, where a better-tolerated PI3K inhibitor could be layered onto existing standards of care, expanding both duration of therapy and total addressable market.
Novartis’ breast cancer portfolio includes the blockbuster drug Kisqali (ribociclib). The drug is a selective, oral cyclin-dependent inhibitor of kinases 4 and 6 (CDK4/6) — two enzymes involved in the control of cell cycle progression.
Kisqali sales totaled $4.8 billion in 2025, up 58%. Sales grew strongly across all regions, including +77% growth in the United States, reflecting continued share gains in metastatic breast cancer, as well as leading NBRx share in early breast cancer.
NVS Navigates Generic Competition for Entresto
2026 is a pivotal year for Novartis as it navigates the largest patent expiry in its history for the cardiovascular drug Entresto.
Last month, Novartis reported mixed results for the fourth quarter of 2025, with earnings beating estimates but revenues missing the same.
Shares of Novartis have gained 29.9% over the past year compared with the industry’s growth of 5.8%.
Image Source: Zacks Investment Research
Sales are being adversely impacted by generic competition for key drugs, Entresto (the United States) and Promacta.
Novartis is now banking on key growth drivers — Kisqali, Kesimpta, Pluvicto and Scemblix — to support top-line growth.
Pipeline progress remains a major upside, with multiple potential multi-blockbusters advancing through FDA approvals and positive phase III data across Rhapsido, Pluvicto, Itvisma and ianalumab.
The company recently acquired Avidity Biosciences, Inc., adding the latter’s differentiated muscle-targeting antibody oligonucleotide conjugate (AOC) platform and three late-stage programs, further strengthening its industry-leading neuromuscular pipeline.
The transaction could unlock multi-billion-dollar market opportunities, with potential product launches targeted before 2030. It also enhances Novartis’ late-stage pipeline, supporting the company’s projected 2025-2030 net sales CAGR of 5-6% at constant currency and reinforcing its mid- to long-term growth outlook.
NVS’ Zacks Rank and Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the pharma/biotech sector are Liquidia Corporation (LQDA - Free Report) , ADMA Biologics (ADMA - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . While LQDA currently sports a Zacks Rank #1 (Strong Buy), ADMA and ANIP carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for LQDA’s earnings per share (EPS) have more than doubled to $1.75 in the past 30 days. Shares of LQDA have soared 63.1% over the past six months.
Over the past 60 days, estimates for ADMA’s 2026 EPS have increased from 85 cents to 96 cents. ADMA’s shares have lost 24.1% over the past year.
Over the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have surged 16.4%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
Key Takeaways
Novartis (NVS - Free Report) is doubling down on precision oncology with a targeted bolt-on acquisition that strengthens its position in one of the largest segments of breast cancer.
Novartis has agreed to acquire a pan-mutant–selective PI3Kα inhibitor program from Synnovation Therapeutics, anchored by lead asset SNV4818.
The transaction aligns squarely with Novartis’ oncology strategy in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer — a large and well-characterized market where innovation has increasingly shifted toward targeted and combination therapies.
Financial Terms of NVS’ Deal With Synnovation
The deal includes a $2 billion upfront payment and up to $1 billion in milestones, signaling high conviction in the program despite its early-stage status.
The transaction is slated to be closed in the first half of 2026.
Strategic Rationale Behind NVS’ Acquisition
SNV4818 is designed to target the mutated PI3Kα enzyme found in cancer cells while sparing the wild-type (normal) PI3Kα in healthy cells.
Approximately 40% of HR+/HER2- breast cancer patients harbor PIK3CA mutations, a subgroup associated with poorer prognosis. This creates a sizable, biomarker-defined patient population where targeted therapies can command premium pricing and strong adoption, provided they demonstrate clear differentiation.
Earlier-generation PI3K inhibitors have struggled with tolerability due to off-target effects on normal cells, often limiting dosing intensity and duration.
By contrast, SNV4818’s mutant-selective approach aims to improve tolerability and safety, enable more consistent dosing, expand usage in earlier lines of therapy, and enhance combination potential with endocrine therapy and CDK inhibitors.
SNV4818 is currently in phase I/II development.
For Novartis, this opportunity is not just about monotherapy potential. The real upside lies in combination regimens, where a better-tolerated PI3K inhibitor could be layered onto existing standards of care, expanding both duration of therapy and total addressable market.
Novartis’ breast cancer portfolio includes the blockbuster drug Kisqali (ribociclib). The drug is a selective, oral cyclin-dependent inhibitor of kinases 4 and 6 (CDK4/6) — two enzymes involved in the control of cell cycle progression.
Kisqali sales totaled $4.8 billion in 2025, up 58%. Sales grew strongly across all regions, including +77% growth in the United States, reflecting continued share gains in metastatic breast cancer, as well as leading NBRx share in early breast cancer.
NVS Navigates Generic Competition for Entresto
2026 is a pivotal year for Novartis as it navigates the largest patent expiry in its history for the cardiovascular drug Entresto.
Last month, Novartis reported mixed results for the fourth quarter of 2025, with earnings beating estimates but revenues missing the same.
Shares of Novartis have gained 29.9% over the past year compared with the industry’s growth of 5.8%.
Image Source: Zacks Investment Research
Sales are being adversely impacted by generic competition for key drugs, Entresto (the United States) and Promacta.
Novartis is now banking on key growth drivers — Kisqali, Kesimpta, Pluvicto and Scemblix — to support top-line growth.
Pipeline progress remains a major upside, with multiple potential multi-blockbusters advancing through FDA approvals and positive phase III data across Rhapsido, Pluvicto, Itvisma and ianalumab.
The company recently acquired Avidity Biosciences, Inc., adding the latter’s differentiated muscle-targeting antibody oligonucleotide conjugate (AOC) platform and three late-stage programs, further strengthening its industry-leading neuromuscular pipeline.
The transaction could unlock multi-billion-dollar market opportunities, with potential product launches targeted before 2030.
It also enhances Novartis’ late-stage pipeline, supporting the company’s projected 2025-2030 net sales CAGR of 5-6% at constant currency and reinforcing its mid- to long-term growth outlook.
NVS’ Zacks Rank and Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the pharma/biotech sector are Liquidia Corporation (LQDA - Free Report) , ADMA Biologics (ADMA - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . While LQDA currently sports a Zacks Rank #1 (Strong Buy), ADMA and ANIP carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for LQDA’s earnings per share (EPS) have more than doubled to $1.75 in the past 30 days. Shares of LQDA have soared 63.1% over the past six months.
Over the past 60 days, estimates for ADMA’s 2026 EPS have increased from 85 cents to 96 cents. ADMA’s shares have lost 24.1% over the past year.
Over the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $8.28 to $8.99 for 2026. Over the past year, shares of ANIP have surged 16.4%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.